POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, and TerraPower, a leading nuclear innovation company that strives to improve the world through nuclear energy and science, announced recently that they have signed a research and clinical supply agreement for the medical radioisotope actinium-225 (Ac-225), further expanding the number of radioisotopes in POINT’s pipeline for next-generation precision radiopharmaceutical treatments.
Matching the right radioisotope with the right target to create the most effective radioligand therapies is a core pillar of POINT’s clinical development strategy. Actinium-225 is a unique medical isotope with a decay path of 4 high energy alpha particles resulting in very high energy transfer to tumor cells. In addition, the short range of alpha radiation in human tissue and Ac-225’s 9.9-day half-life makes it a very exciting candidate for targeted alpha therapy.
To read more please visit:
Source: Biospace